Sanofi (SNY)
| Market Cap | 132.11B |
| Revenue (ttm) | 44.52B |
| Net Income (ttm) | 7.07B |
| Shares Out | 2.50B |
| EPS (ttm) | 2.75 |
| PE Ratio | 19.23 |
| Forward PE | 12.85 |
| Dividend | $1.30 (2.45%) |
| Ex-Dividend Date | May 4, 2022 |
| Volume | 1,749,845 |
| Open | 52.80 |
| Previous Close | 52.56 |
| Day's Range | 52.60 - 53.14 |
| 52-Week Range | 46.93 - 58.10 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 59.66 (+12.8%) |
| Earnings Date | Apr 28, 2022 |
About SNY
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established p...
Financial Performance
In 2021, Sanofi's revenue was 39.18 billion, an increase of 4.83% compared to the previous year's 37.37 billion. Earnings were 6.22 billion, a decrease of -49.38%.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 33 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is 59.66, which is an increase of 12.78% from the latest price.
News
European Dividend Aristocrats: 40 Top International Dividend Stocks
U.S. equity markets aren't the only place where you can find income-producing royalty. Indeed, a quick look across the pond yields dozens, in the form of the European Dividend Aristocrats.
Sanofi ordered to compensate French family for epilepsy drug side effects
A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker ...
3 Top Biotech Stocks to Buy Right Now
These three pharma stocks each pay market-beating dividends to shareholders.
EuroAPI gains on market debut after spin-off from Sanofi
Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.
Press Release: Foundation S: Sanofi's new philanthropic spearhead
Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foun...
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines.
Sanofi posts higher earnings and sales, sees further growth ahead
Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings p...
Sanofi operating income up 16% on bestseller drug Dupixent
French healthcare group Sanofi's first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
Sanofi continues to deliver strong business EPS ( 1) growth driven by higher sales and improved margins in Q1
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Should You Buy Sanofi (SNY) Ahead of Earnings?
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence
Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company's ambition to attain world-class standards of manufactur...
Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi Medications
Collaboration Supports Companies' Joint Focus on Medication Adherence and Affordability SAN FRANCISCO , April 13, 2022 /PRNewswire/ -- Today, Sempre Health announced compelling outcomes achieved during ...
Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents
The Company's shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 3, 2022 at 2:30 p.m. (CET) at Paris Expo Porte de Versailles – 1, Place de la Porte de Versailles,...
Could This Drug Candidate Be a Blockbuster for Sanofi?
The pharma giant recently shared encouraging results from a late-stage clinical trial for its hemophilia drug candidate.
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?
Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.
Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
Sanofi's DE&I strategy was revamped in June 2021 with set objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can brin...
Sanofi to list drug ingredients business on May 6
Sanofi expects to list its drug ingredients business EUROAPI on May 6, having received approval from French stock market regulator, the pharmaceutical giant said on Friday.
Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
Sanofi announced today that the French Autorité des marchés financiers (AMF) has approved the listing prospectus prepared by EUROAPI
Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals
A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.
France's Sanofi offers 1.5 billion euro bond linked to access to medicine
French healthcare group Sanofi said it had priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).
Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.